Biomaterial Database

Biochemical and functional characterization of central dopamine receptors. 1988

M Goldstein, and J Y Lew, and E Meller

New York University Medical Center, Department of Psychiatry, N.Y. 10016.

In order to characterize the D2 dopamine receptors at the molecular level we have developed procedures for purification and characterization of the receptor binding protein. The ligand binding sites of the D2 dopamine receptor have been identified by photoaffinity labeling with 3H-7-azidofluphenazine. The D2 dopamine receptor protein was partially purified by Fast Performance Liquid Chromatography on a Mono Q column and on a wheat-germ agglutinin agarose column. Some behavioral expressions which are probably mediated by D1 dopamine receptors were described. Evidence was obtained that catalepsy is associated with the blockade of D1 dopamine receptors and that D1 and D2 dopamine receptor systems interact either directly or indirectly in mediating this behavior. The administration of a dopamine agonist to monkeys with unilateral ventromedial tegmental lesions of the brainstem produced a biting behavior which, in some aspects, resembles the behavior in Lesch-Nyhan patients. The prevention of the dopamine agonist-induced biting behavior by the D1 dopamine antagonists indicates that D1 dopamine receptors are involved in the control of the expression of this behavior. The biting behavior, like other motor functions, might be controlled by the mesolimbic dopamine systems, and supersensitive mesolimbic D1 dopamine receptors might be associated with the pathology of this behavior.

UI	MeSH Term	Description	Entries
D011954	Receptors, Dopamine	Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells.	Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D003342	Corpus Striatum	Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE.	Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D017447	Receptors, Dopamine D1	A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES.	Dopamine D1 Receptors,Dopamine-D1 Receptor,D1 Receptors, Dopamine,Dopamine D1 Receptor,Receptor, Dopamine-D1
D017448	Receptors, Dopamine D2	A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.	Dopamine D2 Receptors,Dopamine-D2 Receptor,D2 Receptors, Dopamine,Dopamine D2 Receptor,Receptor, Dopamine-D2
D018492	Dopamine Antagonists	Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.	Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine